- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04442022
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Study Overview
Status
Intervention / Treatment
- Drug: Selinexor (combination therapy)
- Drug: Selinexor (combination therapy)
- Drug: Selinexor (combination therapy)
- Drug: Rituximab (combination therapy)
- Drug: Rituximab (combination therapy)
- Drug: Gemcitabine (combination therapy)
- Drug: Dexamethasone (combination therapy)
- Drug: Cisplatin (combination therapy)
- Drug: Selinexor (continuous therapy)
- Drug: Placebo matching for Selinexor (continuous therapy)
- Drug: Placebo matching for Selinexor (combination therapy)
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Karyopharm Medical Information
- Phone Number: (888) 209-9326
- Email: clinicaltrials@karyopharm.com
Study Locations
-
-
-
Linz, Austria, 4021
- Withdrawn
- Kepler Universitaetskrankenhaus Med Campu III - Onkologie
-
Vienna, Austria, 1090
- Withdrawn
- University of Vienna, Medical Clinic I, Hematology
-
Vienna, Austria, 1130
- Withdrawn
- Hospital Hietzing
-
-
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Completed
- Jiangsu Province Hospital
-
Suzhou, Jiangsu, China, 215006
- Completed
- The First Affiliated Hospital Of Soochow University
-
-
Shanghai
-
Huangpu, Shanghai, China, 200025
- Completed
- Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School
-
Xuhui District, Shanghai, China, 200032
- Completed
- Zhongshan Hospital Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610044
- Completed
- Huaxi Hospital Sichuan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Completed
- The First Affiliated Hospital, Zhejiang University
-
-
-
-
-
Ashdod, Israel, 7747629
- Recruiting
- Assuta Ashdod Medical Center
-
Contact:
- Merav Leiba, MD
- Phone Number: +972 58 666 9161
- Email: meravlei@assuta.co.il
-
Principal Investigator:
- Merav Leiba, MD
-
Beer Sheva, Israel, 8457108
- Recruiting
- Soroka Medical Center
-
Contact:
- Itai Levi, MD
- Phone Number: +972 54 4203424
- Email: etail@clalit.org.il
-
Principal Investigator:
- Itai Levi, MD
-
Haifa, Israel, 3109601
- Withdrawn
- Rambam health care campus (Department of Hematology & Bone Marrow Transplantation)
-
Holon, Israel, 5822012
- Withdrawn
- Wolfson Medical Center
-
Jerusalem, Israel, 9103401
- Withdrawn
- Hadassah Medical Center
-
Petach Tikva, Israel, 4941492
- Recruiting
- Rabin Medical Center
-
Principal Investigator:
- Ronit Gurion, MD
-
Contact:
- Ronit Gurion, MD
- Phone Number: +972 50 406 5336
- Email: Ronitgurion@gmail.com
-
Tel Aviv, Israel, 6423906
- Withdrawn
- Sourasky Medical Center
-
Tel aviv, Israel, 6423906
- Recruiting
- Assuta medical centers - Ramat Hachayal
-
Contact:
- Ofer Shpilberg, MD
- Phone Number: 97237644942
- Email: ofers@assuta.co.il
-
Principal Investigator:
- Ofer Shpilberg, MD
-
-
-
-
-
Ancona, Italy, 60020
- Recruiting
- AOU Ospedali Riuniti-Università Politecnica delle Marche Clinica di Ematologia
-
Principal Investigator:
- Guido Gini, MD
-
Contact:
- Guido Gini, MD
- Phone Number: +39 71 596 4562/4235
- Email: guido.gini@ospedaliriuniti.marche.it
-
Bologna, Italy, 40138
- Not yet recruiting
- AOU Policlinico S.Orsola Malpighi di Bologna, University of Bologna
-
Principal Investigator:
- Pier Luigi Zinzani, MD
-
Contact:
- Pier Luigi Zinzani, MD
- Phone Number: +39 51 214 3680
- Email: pierluigi.zinzani@unibo.it
-
Caserta, Italy, 81100
- Recruiting
- UOC Ematologia ad Indirizzo Oncologico, AORN "Sant'Anna e San Sebastiano"
-
Contact:
- Ferdinando Frigeri, MD
- Phone Number: +39 82 323 2192
- Email: ferdinando.frigeri@aorncaserta.it
-
Principal Investigator:
- Ferdinando Frigeri, MD
-
Novara, Italy, 28100
- Recruiting
- AOU Maggiore della Carità SCDU Ematologia
-
Principal Investigator:
- Gianluca Gaidano, MD
-
Contact:
- Gianluca Gaidano, MD
- Phone Number: +39 321 373 2194
- Email: gianluca.gaidano@med.uniupo.it
-
Pescara, Italy, 65124
- Recruiting
- DIP. Oncologia- Ematologia, UOSD Centro Diagnosie TerapiaDei Linfomi
-
Principal Investigator:
- Elsa Pennese, MD
-
Contact:
- Elsa Pennese, MD
- Phone Number: +39 347 307 9075
- Email: elsapennese@gmail.com
-
Rome, Italy, 00168
- Recruiting
- Fondatione Policlinico Universitario A. Gemelli
-
Contact:
- Stefan Hohaus, MD
- Phone Number: +39 63 015 4180
- Email: stefan.hohaus@unicatt.it
-
Principal Investigator:
- Stefan Hohaus, MD
-
-
Napoli
-
Naples, Napoli, Italy, 1-80131
- Recruiting
- National Cancer Institute
-
Contact:
- Antonio Pinto, MD
- Phone Number: +39 81 590 3382
- Email: a.pinto@istitutotumori.na.it
-
Principal Investigator:
- Antonio Pinto, MD
-
-
Sicilia
-
Palermo, Sicilia, Italy, 90146
- Recruiting
- Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
-
Contact:
- Caterina Patti, MD
- Phone Number: +39 91 780 2037
- Email: k.patti@ospedaliriunitipalermo.it
-
Principal Investigator:
- Caterina Patti, MD
-
-
Torino
-
Turin, Torino, Italy, 10126
- Not yet recruiting
- AOU City of Health and Science of Turin
-
Principal Investigator:
- Federica Cavallo, MD
-
Contact:
- Federica Cavallo, MD
- Phone Number: +39 11 633 4264
- Email: f.cavallo@unito.it
-
-
-
-
-
Warsaw, Poland, 00-791
- Not yet recruiting
- Institute of Hematology and Transfusion Medicine
-
Principal Investigator:
- Ewa Lech-Maranda, MD
-
Contact:
- Ewa Lech-Maranda, MD
- Phone Number: 48223496454
- Email: emaranda@ihit.waw.pl
-
Warszawa, Poland, 02-781
- Recruiting
- Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology
-
Principal Investigator:
- Jan Walewski, MD
-
Contact:
- Jan Walewski, MD
- Phone Number: +48 22 546 3248
- Email: jan.walewski@pib-nio.pl
-
-
Lesser
-
Krakow, Lesser, Poland, 30-510
- Recruiting
- Pratia MCM Krakow
-
Contact:
- Wojciech Jurczak, MD
- Phone Number: 48602338290
- Email: wojciech.jurczak@pratia.com
-
Principal Investigator:
- Wojciech Jurczak, MD
-
-
Pomerania
-
Gdynia, Pomerania, Poland, 81-519
- Recruiting
- Szpitale pomorskie gdynia dept of haematology
-
Contact:
- Wanda Knopinska-Posluszny, MD
- Phone Number: +48 58 726 0570
- Email: wanda.knopinska@gmail.com
-
Principal Investigator:
- Wanda Knopinska-Posluszny, MD
-
-
Radeckiego
-
Wroclaw, Radeckiego, Poland, 50-367
- Recruiting
- Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytecki Szpital Kliniczny im. Jana Mikulicza - Radeckiego we Wrocławiu
-
Contact:
- Tomasz Wrobel
- Email: tomasz_wrobel@wp.pl
-
Principal Investigator:
- Tomasz Wrobel
-
-
Wielkopolska
-
Skorzewo, Wielkopolska, Poland, 60819
- Recruiting
- CM Pratia Poznań
-
Principal Investigator:
- Maciej Kazmierczak, MD
-
Contact:
- Maciej Kazmierczak, MD
- Phone Number: +48506969916
- Email: maciej.kazmierczak@onet.eu
-
-
Śląskie
-
Katowice, Śląskie, Poland, 40-523
- Recruiting
- Pratia Onkologia Katowice
-
Contact:
- Sebastian Grosicki
- Phone Number: +48 501 714 089
- Email: sgrosicki@wp.pl
-
Principal Investigator:
- Sebastian Grosicki
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Vall Hebron
-
Principal Investigator:
- Pau Abrisqueta, MD
-
Contact:
- Pau Abrisqueta, MD
- Phone Number: 4895 +34 93 489 3000
- Email: pabrisqueta@vhebron.net
-
Barcelona, Spain, 09809
- Recruiting
- Institut Catala D'oncolocia
-
Contact:
- Anna Sureda, MD
- Phone Number: +34 93 260 7750
- Email: asureda@iconcologio.net
-
Principal Investigator:
- Anna Sureda, MD
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz
-
Contact:
- Victor Jiménez Yuste, MD
- Phone Number: +34 91 727 7116
- Email: vjimenezy@salud.madrid.org
-
Principal Investigator:
- Victor Jiménez Yuste, MD
-
Seville, Spain, 41013
- Recruiting
- Hospital Virgen del Rocío
-
Contact:
- Fatima De la Cruz, MD
- Phone Number: +34 95 501 3277
- Email: fatimadelacruzv@gmail.com
-
Principal Investigator:
- Fatima De la Cruz, MD
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Recruiting
- Institut català d'oncologia-hospital germans trias i pujol
-
Contact:
- Juan Manuel Sancho, MD
- Phone Number: +34 93 497 8987
- Email: jsancho@iconcologia.net
-
Principal Investigator:
- Juan Manuel Sancho, MD
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Recruiting
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
-
Contact:
- Sujith Kalmadi, MD
- Phone Number: 480-821-2838
- Email: kalmadi@ironwoodcrc.com
-
Principal Investigator:
- Sujith Kalmadi, MD
-
Tucson, Arizona, United States, 85711
- Recruiting
- Arizona Oncology Associates
-
Principal Investigator:
- Sudhir Manda, MD
-
Contact:
- Sudhir Manda, MD
- Phone Number: 520-886-0206
- Email: sudhir.manda@usoncology.com
-
-
California
-
Cerritos, California, United States, 90703
- Recruiting
- The Oncology Institute (TOI) Clinical Research
-
Principal Investigator:
- Amitabha Mazumder, MD
-
Contact:
- Amitabha Mazumder, MD
- Email: amitabhamazumder@theoncologyinstitute.com
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Withdrawn
- Investigative Clinical Research of Indiana, LLC
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Recruiting
- Norton Cancer Institute, St. Matthews
-
Contact:
- Don Stevens, MD
- Phone Number: 502-899-3366
- Email: don.stevens@nortonhealthcare.org
-
Principal Investigator:
- Don Stevens, MD
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Withdrawn
- Tulane Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland Greenebaum Comprehensive Cancer Center
-
Contact:
- Seung Tae Lee, MD
- Phone Number: 410-328-8708
- Email: seunglee@umm.edu
-
Principal Investigator:
- Seung Tae Lee, MD
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Withdrawn
- Comprehensive Cancer Centers of Nevada - Town Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- Withdrawn
- New Mexico Cancer Care Alliance
-
-
New York
-
Stony Brook, New York, United States, 11794
- Recruiting
- Stony brook
-
Contact:
- Thomas Jandl, MD
- Phone Number: 631-638-1000
- Email: thomas.jandl@stonybrookmedicine.edu
-
Principal Investigator:
- Thomas Jandl, MD
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Withdrawn
- Gabrail Cancer Center Research LLC
-
-
Texas
-
Dallas, Texas, United States, 75230
- Withdrawn
- Texas Oncology - Medical City Dallas
-
Dallas, Texas, United States, 75231
- Withdrawn
- Texas Oncology - Presbyterian Dallas Cancer Center
-
Dallas, Texas, United States, 75246
- Withdrawn
- Texas Oncology - Sammons
-
Fort Worth, Texas, United States, 76104
- Withdrawn
- Texas Oncology - Fort Worth
-
Plano, Texas, United States, 75075
- Withdrawn
- Texas Oncology - Plano East
-
Tyler, Texas, United States, 75702
- Recruiting
- Texas Oncology - Tyler
-
Principal Investigator:
- Habte Yimer, MD
-
Contact:
- Habte Yimer, MD
- Phone Number: 903-579-9800
- Email: habte.yimer@usoncology.com
-
Tyler, Texas, United States, 75702
- Recruiting
- The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center
-
Contact:
- Marc Usrey, MD
- Phone Number: 903-595-7044
- Email: Marc.Usrey@uthct.edu
-
Principal Investigator:
- Marc Usrey, MD
-
-
Washington
-
Everett, Washington, United States, 98201
- Withdrawn
- Providence Regional Cancer Partnership
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have pathologically confirmed de novo DLBCL or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma). Patient with high-grade lymphoma with c-MYC, Bcl2 and/or Bcl6 rearrangements are eligible (only for Phase 2). (Documentation to be provided).
Have received at least 1 but no more than 3 prior lines of systemic therapy for the treatment of DLBCL with relapsed or refractory disease following their most recent regimen.
- Salvage chemoimmunotherapy followed by stem cell transplantation will be considered as 1 line of systemic therapy.
- Maintenance therapy will not be counted as a separate line of systemic therapy.
- Radiation with curative intent for localized DLBCL will not be counted as 1 line of systemic therapy.
- Positron emission tomography (PET) positive measurable disease with at least 1 node having the longest diameter (LDi) greater than (>) 1.5 centimeter (cm) or 1 extranodal lesion with LDi >1 cm (per the Lugano Criteria 2014). The Deauville 5-point scale (D5PS) score assessed on the FDG PET/CT should be between 3 to 5.
- Not intended for HSCT or CAR-T cell therapy based on objective clinical criteria determined by the treating physician. Patients who cannot receive HSCT due to active disease are allowed on study (up to approximately 15 percent [%] of patients enrolled in each Phase). Documentation on lack of intention to proceed to receive HSCT or CAR-T therapy must be provided by the treating physician.
Adequate bone marrow function at screening, defined as:
- Absolute neutrophil count (ANC) ≥1*10^9 per liter (/L).
- Platelet count ≥100*10^9/L (without platelet transfusion less than [<] 14 days prior to Cycle 1 Day 1 [C1D1]).
- Hemoglobin ≥8.5 gram per deciliter (g/dL) (without red blood cell transfusion <14 days prior to C1D1).
- Circulating lymphocytes less than or equal to (≤) 50*10^9/L.
Adequate liver and kidney function, defined as:
- Aspartate transaminase (AST) or alanine transaminase (ALT) ≤2.5*upper limit of normal (ULN), or ≤5*ULN in cases with known lymphoma involvement in the liver.
- Serum total bilirubin ≤2*ULN, or ≤5*ULN if due to Gilbert syndrome or in cases with known lymphoma involvement in the liver.
- Calculated creatinine clearance (CrCl) ≥30 milliliter per minute (mL/min) based on Cockcroft-Gault formula.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
- An estimated life expectancy of >3 months at Screening.
- Patients with primary refractory DLBCL defined as no response or relapse within 6 months after ending first-line treatment, will be allowed in the study.
- Agree to highly effective contraception during the duration of the study with contraception use continuing for 12 months after the last dose of study treatment
- Female patients of childbearing potential must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment (except patients with Non-Childbearing potential: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy).
- Male patients who are sexually active must use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment. Male patients must agree not to donate sperm during the study treatment period and for 12 months following the last dose of study treatment.
Exclusion Criteria:
- DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkin's lymphoma + non-Hodgkin's lymphoma [NHL]), DLBCL transformed from diseases other than indolent NHL; primary mediastinal (thymic) large B-cell lymphoma (PMBL); T-cell rich large B-cell lymphoma.
- Previous treatment with selinexor or other XPO1 inhibitors.
- Contraindication to any drug contained in the combination therapy regimen (SR-GDP).
- Known active central nervous system or meningeal involvement by DLBCL at time of Screening.
- Use of any standard or experimental anti-DLBCL therapy (including nonpalliative radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy) <21 days prior to C1D1 (prednisone <30 mg or equivalent is permitted; palliative radiation is permitted only if on non-target lesions).
- Any AE, by C1D1, which has not recovered to Grade ≤1 (Common Terminology Criteria for Adverse Events [CTCAE], v.5.0), or returned to baseline, related to the previous DLBCL therapy, except hematological abnormalities (as specified in the inclusion criteria) and alopecia.
- Major surgery <14 days of Cycle 1 Day 1.
Hematopoietic stem cell transplantation/CAR-T therapy as follows:
- Autologous stem cell transplant (SCT) <100 days or allogeneic-SCT <180 days prior to C1D1
- Active graft-versus-host disease (GVHD) after allogeneic SCT (or cannot discontinue GVHD treatment or prophylaxis)
- CAR-T cell infusion <90 days prior to Cycle 1
- Neuropathy Grade ≥2 (CTCAE, v.5.0).
- Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety, or being compliant with the study procedures.
- Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable (including parenteral).
Patient with active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infections:
- Patient with active HBV are allowed if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is <100 International units (IU)/mL prior to first dose of study treatment.
- Patients with known history of HCV or found to be HCV antibody positive on screening, are allowed if there is documentation of negative viral load per institutional standard.
- Patients with HIV are allowed if they have a negative viral load per institutional standard, and no history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections in the last year.
- Inability to swallow tablets, malabsorption syndrome, or any other gastrointestinal (GI) disease or dysfunction that could interfere with absorption of study treatment.
- Breastfeeding or pregnant women.
- Inability or unwillingness to sign an informed consent form (ICF).
- In the opinion of the Investigator, patient who are significantly below their ideal body weight.
- Patients who received a live attenuated vaccine within prior 28 days of the first dose of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 2: Selinexor 60 mg + R-GDP
Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
|
Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: 375 milligram per meter square (mg/m^2) on Day 1; Route of administration: intravenous (IV)
Dose: 375 mg/m^2 on Day 1; Route of administration: IV
Dose: 1000 mg/m^2 on Days 1 and 8; Route of administration: IV
Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Dose: 75 mg/m^2 on Day 1; Route of administration: IV
Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
|
Active Comparator: Phase 2: R-GDP
Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
|
Dose: 375 milligram per meter square (mg/m^2) on Day 1; Route of administration: intravenous (IV)
Dose: 375 mg/m^2 on Day 1; Route of administration: IV
Dose: 1000 mg/m^2 on Days 1 and 8; Route of administration: IV
Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Dose: 75 mg/m^2 on Day 1; Route of administration: IV
|
Experimental: Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mg
Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
|
Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: 375 milligram per meter square (mg/m^2) on Day 1; Route of administration: intravenous (IV)
Dose: 375 mg/m^2 on Day 1; Route of administration: IV
Dose: 1000 mg/m^2 on Days 1 and 8; Route of administration: IV
Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Dose: 75 mg/m^2 on Day 1; Route of administration: IV
Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
|
Experimental: Phase 3: Selinexor (Selected Dose) + R-GDP followed by Placebo
Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
|
Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: 375 milligram per meter square (mg/m^2) on Day 1; Route of administration: intravenous (IV)
Dose: 375 mg/m^2 on Day 1; Route of administration: IV
Dose: 1000 mg/m^2 on Days 1 and 8; Route of administration: IV
Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Dose: 75 mg/m^2 on Day 1; Route of administration: IV
Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
|
Placebo Comparator: Phase 3: Placebo + R-GDP followed by Placebo
Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
|
Dose: 375 milligram per meter square (mg/m^2) on Day 1; Route of administration: intravenous (IV)
Dose: 375 mg/m^2 on Day 1; Route of administration: IV
Dose: 1000 mg/m^2 on Days 1 and 8; Route of administration: IV
Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Dose: 75 mg/m^2 on Day 1; Route of administration: IV
Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
|
Experimental: Phase 2: Selinexor 40 mg + R-GDP
Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
|
Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
Dose: 375 milligram per meter square (mg/m^2) on Day 1; Route of administration: intravenous (IV)
Dose: 375 mg/m^2 on Day 1; Route of administration: IV
Dose: 1000 mg/m^2 on Days 1 and 8; Route of administration: IV
Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
Dose: 75 mg/m^2 on Day 1; Route of administration: IV
Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014
Time Frame: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
|
From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
|
Phase 3: Progression-free Survival (PFS): Based on Lugano Criteria 2014
Time Frame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
|
From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase 2: Overall Survival (OS)
Time Frame: From date of initial randomization until death (maximum of 5 years from randomization)
|
From date of initial randomization until death (maximum of 5 years from randomization)
|
Phase 2: Overall Response Rate at the End of Combination Therapy (ORR-EoC): Based on Lugano Criteria 2014
Time Frame: From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
|
From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
|
Phase 2: Duration of Response (DOR): Based on Lugano Criteria 2014
Time Frame: From time of first response until disease progression or death (maximum of 5 years from randomization)
|
From time of first response until disease progression or death (maximum of 5 years from randomization)
|
Phase 2: Number of Patients with Adverse Events (AEs)
Time Frame: Up to 30 days after last dose of study drug (maximum of 5 years from randomization)
|
Up to 30 days after last dose of study drug (maximum of 5 years from randomization)
|
Phase 2: Progression-free Survival: Based on Lugano Criteria 2014
Time Frame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
|
From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
|
Phase 3: Overall Response Rate: Based on Lugano Criteria 2014
Time Frame: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
|
From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
|
Phase 3: Overall Survival
Time Frame: From date of initial randomization until death (maximum of 5 years from randomization)
|
From date of initial randomization until death (maximum of 5 years from randomization)
|
Phase 2: Overall Response Rate at the End of Combination Therapy: Based on Modified Lugano Criteria
Time Frame: From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
|
From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
|
Phase 3: Overall Response Rate at the End of Combination Therapy: Based on Lugano Criteria 2014
Time Frame: From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
|
From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
|
Phase 3: Overall Response Rate at the End of Combination Therapy: Based on Modified Lugano Criteria
Time Frame: From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
|
From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
|
Phase 3: Duration of Response: Based on Lugano Criteria 2014
Time Frame: From time of first response until disease progression or death (maximum of 5 years from randomization)
|
From time of first response until disease progression or death (maximum of 5 years from randomization)
|
Phase 3: Progression-free Survival: Based on Modified Lugano Criteria
Time Frame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
|
From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
|
Phase 3: Number of Patients with Adverse Events
Time Frame: Up to 30 days after last dose of study drug (maximum of 5 years from randomization)
|
Up to 30 days after last dose of study drug (maximum of 5 years from randomization)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Immunological
- Dexamethasone
- Rituximab
- Gemcitabine
Other Study ID Numbers
- XPORT-DLBCL-030
- 2020-000605-84 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Diffuse Large B-cell Lymphoma
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
Curis, Inc.The Leukemia and Lymphoma SocietyCompletedLymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditionsUnited States
-
Hoffmann-La RocheCompletedRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell LymphomaUnited States, Spain, United Kingdom
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
BeiGeneRecruitingRelapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell LymphomaChina
-
Icahn School of Medicine at Mount SinaiBristol-Myers SquibbCompletedRefractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
Clinical Trials on Selinexor (combination therapy)
-
Karyopharm Therapeutics IncBelgium and Luxembourg Gynaecological Oncology Group; North-Eastern German... and other collaboratorsActive, not recruitingEndometrial CancerUnited States, China, Israel, Spain, Belgium, Germany, Greece, Czechia, Italy, Canada
-
Karyopharm Therapeutics IncGOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaboratorsRecruitingEndometrial CancerUnited States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Slovakia, Canada, Hungary, Czechia, Germany
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Rhabdoid Tumor | Wilms Tumor | Nephroblastoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | XPO1 Gene MutationUnited States
-
The First Hospital of Jilin UniversityRecruitingPTCL Patients Who Achieved Complete Response From Frontline TreatmentChina
-
University of RochesterKaryopharm Therapeutics IncRecruitingSmoldering Multiple MyelomaUnited States
-
University of UtahKaryopharm Therapeutics IncActive, not recruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States
-
Chunrui LiNanjing IASO Biotherapeutics Co.,LtdRecruitingExtramedullary Multiple MyelomaChina
-
Karyopharm Therapeutics IncCompletedHematological MalignanciesUnited States, Denmark, Canada
-
Karyopharm Therapeutics IncTerminatedRichter's TransformationUnited States, Germany, United Kingdom, Spain, Poland
-
Morten Mau-SoerensenHospices Civils de Lyon; Gustave Roussy, Cancer Campus, Grand Paris; Institut... and other collaboratorsUnknownThymoma | Advanced Thymic Epithelial TumourDenmark, France